Journal of VitreoRetinal Diseases最新文献_第2页

Rare Presentation of Attenuated Mucopolysaccharidosis Type IIIA as Isolated Retinitis Pigmentosa. 罕见的减毒粘多糖病IIIA型表现为孤立性色素性视网膜炎。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-05-10 DOI: 10.1177/24741264251340108

Josephine R Seela, Jade Y Moon, Sandra R Montezuma

{"title":"Rare Presentation of Attenuated Mucopolysaccharidosis Type IIIA as Isolated Retinitis Pigmentosa.","authors":"Josephine R Seela, Jade Y Moon, Sandra R Montezuma","doi":"10.1177/24741264251340108","DOIUrl":"https://doi.org/10.1177/24741264251340108","url":null,"abstract":"Purpose: To describe a patient presenting in adulthood with isolated retinopathy found to have mucopolysaccharidosis type IIIA. Methods: A single case was evaluated. Results: A 36-year-old man presented with 5 years of worsening peripheral vision and night vision. The initial examination and testing raised concern for rod-cone dystrophy. Genetic testing with an Invitae Inherited Retinal Disorders Panel showed 2 variants of SGSH, which is associated with mucopolysaccharidosis type IIIA. Laboratory testing showed low heparan-N-sulfatase levels and elevated heparan sulfate levels. These results and a thorough review of the literature support a diagnosis of mild attenuated non-neuronopathic mucopolysaccharidosis type IIIA. Conclusions: This case highlights the necessity for collaboration with genetic counselors and the value of a provider's clinical acumen in interpreting genetic testing results. Furthermore, the importance of considering mucopolysaccharidosis type IIIA when adult patients present with new-onset isolated retinitis pigmentosa is emphasized.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251340108"},"PeriodicalIF":0.5,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12065709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bandage Contact Lens as an Alternative to a Temporary Keratoprosthesis for Vitrectomy With Concurrent Corneal Opacity. 绷带隐形眼镜作为玻璃体切除术并发角膜混浊的临时角膜假体的替代选择。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-05-07 DOI: 10.1177/24741264251340110

Marta Latasiewicz, Mike Adams, Youssef Helmy

引用次数: 0

Purtscher-Like Retinopathy After Acute Ischemic Colitis. 急性缺血性结肠炎后purtscher样视网膜病变。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-05-03 DOI: 10.1177/24741264251338038

Smaran Teru, Cory A Christensen, Jamin Brown

引用次数: 0

Long-Term Follow-up of Cytomegalovirus Retinitis in an Immunocompetent Patient. 免疫功能正常患者巨细胞病毒性视网膜炎的长期随访。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-05-03 DOI: 10.1177/24741264251338042

Michael J Maywood, Lisa J Faia, Tedi Begaj

引用次数: 0

Wavefront Aberrometry in Pseudophakic Patients Before and After Vitrectomy for Bothersome Floaters. 玻璃体切除术前后假晶状体患者的波前像差测定。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-04-29 DOI: 10.1177/24741264251333200

Daniel A Adelberg, Mark T Parsons

{"title":"Wavefront Aberrometry in Pseudophakic Patients Before and After Vitrectomy for Bothersome Floaters.","authors":"Daniel A Adelberg, Mark T Parsons","doi":"10.1177/24741264251333200","DOIUrl":"https://doi.org/10.1177/24741264251333200","url":null,"abstract":"Introduction: To investigate whether the outcome of patients with persistent bothersome floaters who are managed with vitrectomy can be correlated with improvements in higher-order aberrations with wavefront aberrometry. Methods: Pseudophakic patients who had 27-gauge vitrectomy for persistent floaters and whose clinical assessment included preoperative and postoperative wavefront aberrometry were included. The primary outcome was the change in the higher-order aberration percentage measured by wavefront aberrometry. Results: The study included 76 eyes of 66 patients with a mean age (±SD) of 67.8 ± 7.5 years. The Snellen visual acuity improved from 20/32 preoperatively to 20/25 postoperatively (P = .004). Wavefront aberrometry showed a highly significant reduction in the higher-order aberration percentage (P < .000001), with a mean preoperative percentage of 53.9 and a mean postoperative percentage of 38.3. Subgroup analysis found a significant reduction in patients with no previous posterior capsulotomy (P = .001), previous neodymium:YAG capsulotomy (P < .000001), a monofocal intraocular lens (IOL) (P < .000001), and a multifocal IOL (P = .006). There was no significant difference in the mean preoperative and postoperative pupil size, sphere, cylinder, or spherical equivalent. Conclusions: Wavefront aberrometry demonstrates an objective, significant reduction in higher-order aberrations immediately after vitrectomy in pseudophakic patients with bothersome floaters.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251333200"},"PeriodicalIF":0.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12040847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bullous Central Serous Chorioretinopathy Associated With JAK Inhibitor Use. 与JAK抑制剂使用相关的大泡性中央浆液性脉络膜视网膜病变。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-04-25 DOI: 10.1177/24741264251337104

Warren Apel, Ye Li

{"title":"Bullous Central Serous Chorioretinopathy Associated With JAK Inhibitor Use.","authors":"Warren Apel, Ye Li","doi":"10.1177/24741264251337104","DOIUrl":"https://doi.org/10.1177/24741264251337104","url":null,"abstract":"Purpose: To report a case of bullous central serous chorioretinopathy (CSCR) after starting a Janus kinase (JAK) inhibitor and describe the results of focal laser treatment. Methods: A single case was evaluated. Results: A 54-year-old man with rheumatoid arthritis presented with a 2-week history of left superior field loss. His medications included prednisone 10 mg and upadacitinib, which was added to his regimen 3 weeks previously. His visual acuity (VA) was 20/25 OD and 20/30 OS. An ophthalmic examination of the left eye found an ill-defined white lesion of 2 × 3 disc diameters at the macula with an inferior retinal detachment (RD). Optical coherence tomography showed subretinal fibrin with subretinal fluid (SRF) and a pigment epithelial detachment. After a diagnosis of bullous CSCR was made, focal laser application was performed. One year later, the patient's VA recovered to 20/20 with resolved SRF. Conclusions: Bullous CSCR with a serous RD is an uncommon subtype of pachychoroid disease. Upadacitinib may be associated with its occurrence through disequilibrium of the coagulation cascade. Focal laser treatment offers a favorable outcome for this disease.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251337104"},"PeriodicalIF":0.5,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12031730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intravitreal Aflibercept With vs Without Pneumatic Displacement for Submacular Hemorrhage Associated With Polypoidal Choroidal Vasculopathy. 玻璃体内注射阿非利塞联合与不加气压置换治疗伴息肉样脉络膜血管病变的黄斑下出血。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-04-25 DOI: 10.1177/24741264251335629

Taku Wakabayashi, Chikako Hara, Akihiko Shiraki, Nobuhiko Shiraki, Yoko Fukushima, Susumu Sakimoto, Kaori Sayanagi, Kentaro Nishida, Shigeru Sato, Hirokazu Sakaguchi, Kohji Nishida

{"title":"Intravitreal Aflibercept With vs Without Pneumatic Displacement for Submacular Hemorrhage Associated With Polypoidal Choroidal Vasculopathy.","authors":"Taku Wakabayashi, Chikako Hara, Akihiko Shiraki, Nobuhiko Shiraki, Yoko Fukushima, Susumu Sakimoto, Kaori Sayanagi, Kentaro Nishida, Shigeru Sato, Hirokazu Sakaguchi, Kohji Nishida","doi":"10.1177/24741264251335629","DOIUrl":"https://doi.org/10.1177/24741264251335629","url":null,"abstract":"Purpose: To compare the visual outcomes of intravitreal (IVT) aflibercept with pneumatic displacement vs without pneumatic displacement for submacular hemorrhage (SMH) associated with polypoidal choroidal vasculopathy (PCV). Methods: This retrospective study assessed patients with SMH associated with PCV who were treated with aflibercept and pneumatic displacement with gas (aflibercept+gas group) or with aflibercept alone (monotherapy group). Patients were followed for at least 12 months, with the best-corrected visual acuity (BCVA) at 12 months the primary outcome measure. Results: Forty-seven eyes of 47 patients were retrospectively analyzed from August 2013 to March 2023. The aflibercept+gas group comprised 25 eyes and the monotherapy group, 22 eyes. The 2 groups had comparable baseline characteristics. The mean logMAR best-corrected visual acuity (BCVA) before treatment was 0.78 ± 0.46 in the aflibercept+gas group and 0.83 ± 0.66 in the monotherapy group (P = .76). The mean BCVA (0.26 ± 0.42 vs 0.85 ± 0.57) and the mean change in (-0.52 ± 0.55 vs 0.02 ± 0.75) 12 months postoperatively was significantly better in the aflibercept+gas group than in the monotherapy group (P < .001 and P < .008, respectively). The BCVA improved by 3 or more lines in 60.0% of eyes in the aflibercept+gas group but in only 18.2% of eyes in the monotherapy group. Vitreous hemorrhage developed in 16.0% of eyes in the aflibercept+gas group and in 13.6% of eyes in the monotherapy group and retinal detachment in 4.0% and 0%, respectively (both P = 1.000). Conclusions: Better visual outcomes were achieved with IVT aflibercept and pneumatic displacement than with aflibercept alone for SMH associated with PCV.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251335629"},"PeriodicalIF":0.5,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12031733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer-Associated Retinopathy Presenting as Panuveitis Secondary to Minimally Invasive Follicular Thyroid Carcinoma. 肿瘤相关视网膜病变表现为微创滤泡性甲状腺癌继发的全葡萄膜炎。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-04-25 DOI: 10.1177/24741264251337108

Natalie Arnold, Amit Mishra, Mark Seamone

引用次数: 0

Early Treatment in Patients With Small and Medium-Small Class 2 Gene Expression Profiling Uveal Melanoma to Reduce Mortality. 早期治疗中小2类基因表达谱葡萄膜黑色素瘤可降低死亡率。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-04-25 DOI: 10.1177/24741264251337101

Natalia C González, Victor M Villegas, Aaron S Gold, Azeema Latiff, Timothy G Murray

{"title":"Early Treatment in Patients With Small and Medium-Small Class 2 Gene Expression Profiling Uveal Melanoma to Reduce Mortality.","authors":"Natalia C González, Victor M Villegas, Aaron S Gold, Azeema Latiff, Timothy G Murray","doi":"10.1177/24741264251337101","DOIUrl":"https://doi.org/10.1177/24741264251337101","url":null,"abstract":"Purpose: To evaluate the class 2 gene expression profiling of patients with small and medium-small uveal melanoma, focusing on tumor control, metastases, and mortality. Methods: This retrospective case series evaluated patients treated for small or medium-small uveal melanoma by the same surgeon. Patients with small uveal melanoma were treated with microincision vitrectomy surgery or brachytherapy, and patients with medium-small uveal melanoma were treated with brachytherapy. All patients were gene expression profiling class 2. Results: Forty-two patients (21 with a diagnosis of small melanoma; 21 with a diagnosis of medium-small melanoma) with a mean age of 58 years and a confirmed diagnosis of class 2 gene expression profiling melanoma were identified. The melanoma-specific mortality at the 5-year follow-up was 4.8% (1/21) for patients with small melanoma and 14.3% (3/21) for patients with medium-small melanoma. The rate of melanoma-specific active metastasis at 5 years was 4.8% (1/21) for patients with small melanoma and 14.3% (3/21) for patients with medium-small melanoma. In both groups, the enucleation rate at 5 years was 0%. Conclusions: Small tumor management achieves excellent anatomic and visual outcomes but mandates diagnostic accuracy and defined long-term outcomes as well as follow-up (5-year minimum in this series). Gene expression profiling classification is important in prognostication; however, early treatment of small tumors significantly decreases the predicted mortality and has the greatest potential effect on patient survival, even for class 2 melanomas.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251337101"},"PeriodicalIF":0.5,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12031732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bilateral Sterile Granulomatous Uveitis Caused by Intravitreal Injections of Faricimab. 法瑞昔单抗玻璃体内注射引起双侧无菌性肉芽肿性葡萄膜炎。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-04-21 DOI: 10.1177/24741264251330339

Christine Hill, Dimitrios C Arhontoulis, Huyen Bui, Sarah M DeVaro, Peter H Tang

{"title":"Bilateral Sterile Granulomatous Uveitis Caused by Intravitreal Injections of Faricimab.","authors":"Christine Hill, Dimitrios C Arhontoulis, Huyen Bui, Sarah M DeVaro, Peter H Tang","doi":"10.1177/24741264251330339","DOIUrl":"https://doi.org/10.1177/24741264251330339","url":null,"abstract":"Purpose: To describe a case of severe bilateral granulomatous uveitis caused by treatment with faricimab. Methods: A single case was reviewed. Results: A 79-year-old woman with diabetic macular edema developed severe uveitis OU 16 days after bilateral intravitreal (IVT) injections of faricimab. The patient's visual acuity (VA) was hand motions OD and 20/400 OS. She refused IVT antibiotics at bedside but consented to an emergency pars plana vitrectomy (PPV) OU. The laboratory workup for infectious and autoimmune etiologies was unremarkable, as were bacterial and fungal cultures from the PPV. High-dose systemic steroids were initiated after surgery. The patient's VA recovered to 20/30 OD and 20/25 OS. Conclusions: Reports of severe uveitis resulting from injections of faricimab have been documented. We describe a unique case in which the patient with granulomatous uveitis OU experienced a significant decline in vision. With high-dose systemic steroid therapy and surgical intervention, her VA recovered to near baseline.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251330339"},"PeriodicalIF":0.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12012491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0